01/2022. Phase 3 results with MV140 in NEJM Evidence
The results of the phase 3 clinical trial with MV140 for the prevention of recurrent urinary tract infections (UTIs) have been published in the journal NEJM Evidence.
MV140 is a sublingual bacterial vaccine developed by INMUNOTEK with effectiveness for the prevention of recurrent urinary tract infections according to previous uncontrolled studies.
The clinical trial now published has been conducted on 240 women with recurrent UTI from Spain and the United Kingdom, of which 2/3 were treated with MV140 for 3 or 6 months, and 1/3 with placebo. The results indicate that MV140 significantly reduced the number of infectious episodes during the study period (1 year) and increased the quality of life of the patients. Adverse drug reactions were mild and infrequent, indicating that MV140 has an excellent safety profile.
